Manuel R. Guerreiro

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Journal: Haematologica

Published: August 01, 2026

ATG16L1 and OPTN as a novel prognostic gene expression signature in acute myeloid leukemia survival.

ATG16L1 and OPTN as a novel prognostic gene expression signature in acute myeloid leukemia survival.

Journal: Frontiers in oncology

Published: January 09, 2026

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Journal: Cancer research communications

Published: December 17, 2025

Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study.

Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study.

Journal: European journal of haematology

Published: November 08, 2025

The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid Leukemia.

The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid Leukemia.

Journal: Cancers

Published: October 20, 2025

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Journal: Blood advances

Published: August 20, 2025

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Journal: Blood advances

Published: August 20, 2025

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: July 02, 2025

Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation.

Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation.

Journal: Leukemia & lymphoma

Published: June 11, 2025

CAR-T cell therapy in T-Cell lymphoblastic leukemia/lymphoma: where do we stand now?

CAR-T cell therapy in T-Cell lymphoblastic leukemia/lymphoma: where do we stand now?

Journal: Expert review of anticancer therapy

Published: June 03, 2025

CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?

CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?

Journal: Current oncology (Toronto, Ont.)

Published: May 05, 2025

Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.

Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.

Journal: JAMA network open

Published: February 25, 2025

Showing 1-12 of 88

Last Updated: 09/26/2026